TargherGDayCPBonoraE. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med2010; 363: 1341–1350.
2.
TargherGByrneCDLonardoA, et al.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol2016; 65: 589–600.
3.
WuSWuFDingY, et al.Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep2016; 6: 33386–33386.
4.
Janssen A, Grobbee DE and Dendale P. Non-alcoholic fatty liver disease, a new and growing risk indicator for cardiovascular disease. Eur J Prev Cardiol. 2020; 27: 1059–1063.
5.
AlexanderMLoomisAKvan der LeiJ, et al.Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ2019; 367: l5367–l5367.
6.
LauridsenBKStenderSKristensenTS, et al.Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. Eur Heart J2018; 39: 385–393.
7.
Stols-Goncalves D, Hovingh GK, Nieuwdorp M, et al. NAFLD and Atherosclerosis: two sides of the same dysmetabolic coin? Trends Endocrinol Metab 2019; 30: 891–902.
8.
AbelesRDMullishBHForlanoR, et al.Derivation and validation of a cardiovascular risk score for prediction of major acute cardiovascular events in non-alcoholic fatty liver disease; the importance of an elevated mean platelet volume. Aliment Pharmacol Ther2019; 49: 1077–1085.
Bahls M, Lorenz MW, Dorr M, et al. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. Eur J Prev Cardiol. 2020; 27: 234–243.
11.
FadaeiRPoustchiHMeshkaniR, et al.Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis. Sci Rep2018; 8: 11691–11691.
12.
DongiovanniPPettaSMaglioC, et al.Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology2015; 61: 506–514.
13.
SimonsNIsaacsAKoekGH, et al.PNPLA3, TM6SF2, and MBOAT7 genotypes and coronary artery disease. Gastroenterology2017; 152: 912–913.
14.
DongiovanniPMeroniMBaselliG, et al.PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. J Lipid Res2019; 60: 1144–1153.
15.
MacchiCBanachMCorsiniA, et al.Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents. Eur J Prev Cardiol2019; 26: 930–949.
16.
RuscicaMFerriNMacchiC, et al.Liver fat accumulation is associated with circulating PCSK9. Annals of Medicine2016; 48: 384–391.
17.
StahlEPDhindsaDSLeeSK, et al.Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review. J Am Coll Cardiol2019; 73: 948–963.
18.
Pastori D, Sciacqua A, Marcucci R, et al. Prevalence and impact of nonalcoholic fatty liver disease in atrial fibrillation. Mayo Clinic Proceedings. Epub ahead of print 18 November 2019. DOI: 10.1016/j.mayocp.2019.08.027.
19.
El-AgroudyNNKurzbachARodionovRN, et al.Are lifestyle therapies effective for NAFLD treatment?Trends Endocrinol Metab2019; 30: 701–709.
20.
Koutoukidis DA, Astbury NM, Tudor KE, et al. Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis. JAMA Intern Med. Epub ahead of print 1 July 2019. DOI: 10.1001/jamainternmed.2019.2248.
21.
Meroni M and Longo M. The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies. Nutrients 2019; 11: 2642.
